Det vi har behov for å vite noe om er antall nye innleggelser - ikke kun bekreftet antall tilfeller. De inkluderer fra en populasjon av innlagte pasienter
1 Like
Har denne artikkelen blitt diskutert tidligere?
AXL Promotes SARS-CoV-2 Infection of Pulmonary and Bronchial Epithelial Cells
De konkluderer med
Taken together, our findings suggest AXL may play an important role in promoting SARS-CoV-2 infection of the human respiratory system and is a potential target in future clinical intervention strategies.
Vel og bra, men så sier de dette i diskusjonsdelen:
As AXL is overexpressed in numerous cancer types, it has already been pursued as a drug target. However, we note that most reported AXL inhibitors target its kinase domain and would thus not have efficacy against SARS-CoV-2 infection because the virus interacts with the extracellular Ig-like domains of AXL ( Figs. 4 g-i ). Alternative approaches include targeting the AXL extracellular Ig-like domains and the region of the SARS-CoV-2 S protein that interacts with AXL. Clinical grade human recombinant soluble AXL may be used to block viral infection ( Figs. 6 c-g ).
Er Bemcentinib av den typen de er skeptiske til (targets the kinase domain)? Noen som kan dette godt nok til å svare?
Ville vanligvis tagget @larsmkn for å få svar, men han har kanskje fått skriveforbud av Arctic?
6 Likes
Hvorfor trekker alle tilbake innlegg? Lekket info?
Tekbot som leker med oss og sender melding om nyheter og stopp i handel. Men tror den bare har en bug, og det er nyhetene fra fredag som sendes på nytt 
2 Likes
Sannsynligvis fordi TekBot spammer gamle nyheter.
2 Likes
Et anslag på antall innleggelser per dag er 12-15% av nye tilfeller. Sannsynligvis med noen dagers forsinkelse siden det tar litt tid før man blir syk nok til å bli innlagt.
3 Likes
Hvis dette viser seg å fungere hos mennesker, og det lar seg masseprodusere raskt, hva slags konsekvenser får det for BGBIO sin studie?
… that Ab8 is highly effective in preventing and treating SARS-CoV-2 infection in mice and hamsters.
Veldig koselig at det funker på mus og rotter 
Så de har minst 5års jobb for å bekrefte at det Kanskje er trygt og at det kanskje funker på mennesker og 
4 Likes
Vel, det meste som har noe med Covid-19 å gjøre har jo en form for fast track nå for tiden, så det skulle ikke forundre meg om de kunne ha noe klart vesentlig tidligere…
Tror du har misforstått ‘fast track’ konseptet! For å få fast track må en preparat gå gjennom en laaaannnng løp å bekrefte trygghet og efficacy! Selveste Bem. har ikke fåttnoe tross for å ha vist safety og efficacy gjennom flere år
1 Like
Godt mulig det, jeg er langt fra noen ekspert på feltet. Men alle vaksineprogrammer har vel fått forenklet sine sikkerhetsstudier betraktelig ift hva som er vanlig?
Det stemmer , og er grunnen til at jeg ikke skal være labrotte for en eksperimentell og politisk lobbyfisert vaksine. Men gode gamle og godt sikkerhetstestede Bemcentinib tar jeg anytime👍🏻
6 Likes
BERGENBIO TO PRESENT AT SACHS ANNUAL BIOTECH IN EUROPE FORUM
Bergen, Norway, 18 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that CEO Richard Godfrey will be presenting at the Sachs Annual Biotech in Europe Forum.
Date and time: Wednesday 23 September at 1pm CET.
Register for the event here: https://www.sachsforum.com/20bef-registration.html
The presentation will be made available on the Company website in the Presentations section on the day.
www.bergenbio.com/investors/presentations/
– END –
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body’s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
6 Likes
En regneøvelse: Hvor mange klinikker i Sør-Afrika må de ha hvis de skal være ferdig innrullert i starten av November? Mitt estimat: Det holder at ETT stort sykehus eller TO-TRE middels store sykehus starter behandling i neste uke.
Jeg tar utgangspunkt i denne rapporten
Beregner gjennomsnittlig antall innleggelser per klinikk per uke.
Antar at trenden faller omtrent lineært de neste ukene.
Summerer antall innlagte per klinikk for de neste 5 ukene.
Antar at de kan velge klinikker som er minst dobbelt så store som gjennomsnittet.
Edit: Beklager rot i første posten.
Regnet feil. Reposter når jeg har rettet opp.
Edit: rettet opp nå med mye mer lovende resultat.
Noen som følger presentasjonen?
BERGENBIO RECEIVES APPROVAL FROM NORWEGIAN REGIONAL ETHICS COMMITTEE FOR COVID-19 SOUTH AFRICA TRIAL
6 Likes
BERGENBIO FÅR GODKJENNING FRA REK (REGIONAL ETISK KOMITÉ) FOR COVID-19 FORSØK I SØR-AFRIKA
22 Likes
ENDELIG!!!
Neste blir det FPD! I hvert fall i følge RG ila september!
Dvs shortsen må skynde seg. Det er bare 4 børsdager igjen
9 Likes
Lets hope imminently is tomorrow 
2 Likes